Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > now is the time
View:
Post by antoninus on Aug 04, 2010 10:07am

now is the time

now is the time to push forward on finding a partner for TX....this IS the main driver of this company....it NEVER was uveitis...it was ALWAYS transplant. When is this company going to go and find a suitable partner for TX? and what of psoriasis????

you see, because these other indications were sidelined while uveitis became the darling, we are now VULNERABLE.

My gut tells me that someone involved in TX is fully aware of this development, and WILL look at us not necessarily as a partner, but as a TAKEOVER....i mean, for a paltry sum, someone could take this whole drug, lock stock and barrel out for what? 50, 60 million or less?   

and by the way, how is it that a few outstanding issues have turned into a whole new trial? could the fda have been swayed by say a giant pharma in the TX field?
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities